Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Genitourinary 1Endocrine 1

Conditions

Thyroid Cancer, Papillary 1Solid Cancers 1Obesity 1Neoplasms 1Carcinoma, Renal Cell 1Breast Neoplasms 1Adenocarcinoma, Follicular 1

Interventions

Trastuzumab 2Iodine-131 2vandetanib 1tumor necrosis factor-alpha, CNGRC fusion protein, human 1tipifarnib 1pazopanib 1mercaptoundecahydrododecaborate 1Triiodothyronine 1Surgical Procedures, Operative 1Semaxinib 1Rosiglitazone 1Photochemotherapy 1Paclitaxel 1Interleukin-12 Subunit p35 1Interleukin-12 1Docetaxel 1Congresses as Topic 1Azacitidine 14-boronophenylalanine-fructose 12-(1-hexyloxyethyl)-2-devinyl pyropheophorbide-a 11-phenyl-3,3-dimethyltriazene 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Adenocarcinoma, Follicular × Rosiglitazone × Clear all
NCT01100619 2013-09-19

A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid Tumors

Exelixis

Phase 1 Completed
40 enrolled
EndocrineGenitourinaryHead & Neck

Thyroid Cancer, Papillary, Carcinoma, Renal Cell, Adenocarcinoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡